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Abstract
Background: Diabetes is highly prevalent and contributes to significant morbidity and mortality worldwide. Behaviour
change interventions that target health and lifestyle factors associated with the onset of diabetes can delay progression
to diabetes, but many approaches rely on intensive one-to-one contact by specialists. Health coaching is an approach
based on motivational interviewing that can potentially deliver behaviour change interventions by non-specialists at a
larger scale. This trial protocol describes a randomized controlled trial (CATFISH) that tests whether a web-enhanced
telephone health coaching intervention (IGR3) is more acceptable and efficient than a telephone-only health coaching
intervention (IGR2) for people with prediabetes (impaired glucose regulation).
Methods: CATFISH is a two-parallel group, single-centre individually randomized controlled trial. Eligible participants
are patients aged ≥18 years with impaired glucose regulation (HbA1c concentration between 42 and 47 mmol/mol),
have access to a telephone and home internet and have been referred to an existing telephone health coaching
service at Salford Royal NHS Foundation Trust, Salford, UK. Participants who give written informed consent will be
randomized remotely (via a clinical trials unit) to either the existing pathway (IGR2) or the new web-enhanced pathway
(IGR3) for 9 months. The primary outcome measure is patient acceptability at 9 months, determined using the Client
Satisfaction Questionnaire. Secondary outcome measures at 9 months are: cost of delivery of IGR2 and IGR3, mental
health, quality of life, patient activation, self-management, weight (kg), HbA1c concentration, and body mass index. All
outcome measures will be analyzed on an intention-to-treat basis. A qualitative process evaluation will explore the
experiences of participants and providers with a focus on understanding usability of interventions, mechanisms of
behaviour change, and impact of context on delivery and user acceptability. Qualitative data will be analyzed using
Framework.
Discussion: The CATFISH trial will provide a pragmatic assessment of whether a web-based information technology
platform can enhance acceptability of a telephone health coaching intervention for people with prediabetes. The
data will prove critical in understanding the role of web applications to improve engagement with evidence-based
approaches to preventing diabetes.
Trial registration: ISRCTN16534814. Registered on 7 February 2016.
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Background
Diabetes is a long-term condition characterized by hyper-
glycaemia in the presence of defects of insulin secretion or
insulin action, or both, and is a major cause of morbidity
and premature mortality globally [1]. At present, 3.4
million adults in the UK are diagnosed with diabetes, the
majority with type 2 diabetes [2]. The damaging effects of
uncontrolled hyperglycaemia can cause macrovascular
complications (coronary artery disease, peripheral arterial
disease and stroke) and microvascular complications
(diabetic nephropathy [kidney disease], neuropathy [nerve
damage], which can lead to non-traumatic lower limb am-
putations, and retinopathy, which can lead to blindness)
[3]. Altogether, the impact of diabetes is thus significant,
with serious implications for health and quality of life, and
costs to health care systems. In England, the direct cost to
the National Health Service (NHS) of treating type 2
diabetes is approximately £8.8 billion annually, with a fur-
ther £13 billion associated with indirect costs; these costs
are estimated to rise to £15.1 and £20.5 billion, respect-
ively, by 2035–6 [4].
Obesity, physical inactivity and diet are among key risk
factors for type 2 diabetes. Weight gain and obesity are es-
pecially implicated in the onset of type 2 diabetes. Obese
women are nearly 13 times more likely to develop type 2
diabetes than non-obese women; obese men are over 5
times as likely to develop type 2 diabetes [5]. Furthermore,
a 1 kg/m2 increase in body mass index increases the risk
of impaired fasting glucose by 9.5 % [6]. Impaired fasting
glucose or impaired glucose tolerance indicate impaired
glucose regulation, which is a condition where blood
glucose levels are raised, but the levels are insufficient to
meet current thresholds for a clinical diagnosis of type 2
diabetes. Impaired fasting glucose is associated with a
raised hepatic glucose output, whereas impaired glucose
tolerance is associated with peripheral insulin resistance.
There is strong and consistent evidence that people with
impaired fasting glucose or impaired glucose tolerance
have between a 6- and 12-fold risk of developing diabetes,
compared with people without, and both are risk factors
for fatal and non-fatal cardiovascular events [7].
However, it is well established that lifestyle interventions
that target modifiable risk factors such as weight and
physical activity can prevent the onset of diabetes in
people with impaired glucose regulation. A systematic
review of 36 trials showed that diabetes prevention
programmes that included diet or physical activity inter-
ventions can significantly reduce progression to type 2
diabetes and reduce weight and glucose at 12–18 months,
compared with usual care [8]. As such, identification of
people with impaired glucose regulation and intervention
with lifestyle-change programmes presents significant
opportunities for reducing the future incidence of type
2 diabetes. The delivery of these behaviour change
interventions is central to guidance from the National
Institute for Health and Care Excellence (NICE) on
prevention of diabetes in high-risk groups, including
people with impaired glucose regulation. However, the
delivery of NICE-recommended diabetes prevention
programmes is contingent on the availability of special-
ist staff to provide intensive interventions to relatively
small numbers of people over 9 to 18 months. As artic-
ulated by the NHS National Diabetes Prevention
Programme, the challenge remains to scale up and rap-
idly roll out evidence-based behaviour change interven-
tions to ensure that more people at risk of diabetes can
access to such interventions, but without compromis-
ing quality.
Health coaching
A model of care that has potential to achieve diabetes
prevention at a large scale through effective behaviour
change is ‘health coaching’. This is a relatively new
approach and variously defined but common to this
approach is an emphasis on health education and health
promotion via patient-centred coaching based on motiv-
ational interviewing to improve health outcomes [9].
The increasing adoption of telephone and mobile tech-
nologies among patients, and the possibility of delivering
care in efficient and flexible ways, has led to significant
interest in the potential of telephone health coaching
which involves:
a regular series of phone calls between patient and
health professional… to provide support and
encouragement to the patient, and promote healthy
behaviours such as treatment control, healthy diet,
physical activity and mobility, rehabilitation, and
good mental health [10]
However, current evidence of effectiveness is mixed. A
systematic review of 13 randomized controlled trials or
quasi-experimental studies showed that, in 11 studies,
telephone, internet or a combination of telephone, face-
to-face, internet or email health coaching can effectively
improve physical and mental health, promote healthy
behaviours and increase social support among people with
long-term conditions [11]. Other reviews have similarly
identified a number of effective models, although the
important ‘active ingredients’ are not clear [12, 13]. More-
over, much of the evidence is derived from trials con-
ducted in the USA and there is uncertainty about the
benefits of health coaching in the UK. A recent evaluation
of the nurse-led Birmingham OwnHealth telephone health
coaching service for people with long-term conditions
(including diabetes) did not find reductions in health ser-
vice utilization or cost over 12 months [14]. By contrast, a
UK trial of telephone support from non-clinical telecare
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staff (backed up by diabetes specialist nurses) did show
significant improvements in glycaemic control in people
with type 2 diabetes, compared with usual care [15]. This
intervention, now known as Diabetes Care Call, has
recently been adapted for use in people with impaired
glucose tolerance and impaired glucose regulation. A pilot
evaluation (n = 44) of the Care Call intervention in people
with impaired glucose tolerance showed reductions in
weight (2.81 kg, 95 % confidence interval 1.2–4.42), body
mass index (1.06 kg/m2, 95 % confidence interval
0.49–1.63), and fasting blood glucose (0.29 mmol/l, 95 %
confidence interval 0.07–0.51) 1 year after the interven-
tion [16]. Similar outcomes 12 months after the interven-
tion were achieved in a pilot evaluation of Care Call in
people with impaired glucose regulation who were offered
either a telephone-only or a telephone plus group educa-
tion pathway [17]. While the findings of these pilot studies
are limited by the absence of a control group, they offer
proof of concept that telephone health coaching can trans-
late to people with impaired glucose regulation to pro-
mote positive and sustained lifestyle changes to prevent
type 2 diabetes.
The Impaired Glucose Regulation Care Call interven-
tion has recently been enhanced, with greater use of
web-based materials and electronic transfer of patient
data, with a view to making the service more engaging
for patients, and the provision of care more efficient for
providers. The web plus telephone health coaching inter-
vention has been developed by NorthWest EHealth in
partnership with Hitachi Europe Ltd. Patient engagement
is critical to the success of health promotion interventions
and frequent, real-time communication and feedback are
key to behaviour change and empowering patients to
manage their behaviour [18, 19]. Information technology
(IT) platforms, such as desktop applications, mobile short
message service (SMS) and internet-based interventions
are increasingly used to support and enhance patient
engagement in self-management programmes. There is
partial evidence that e-health interventions, described as
second-generation interactive computerized interventions,
can lead to positive improvements in physical activity and
diet in people drawn from community and health settings
[20] and can also support diabetes self-management tasks
[21]. However, the evidence in favour of using IT interven-
tions to support behaviour change is equivocal and few
studies have assessed whether satisfaction and usability
lead to better engagement and less costly delivery [22].
The addition of an IT platform within the Impaired
Glucose Regulation Care Call service might lead to
significant advantages in patient uptake and engagement,
as well as freed human resources for the provider, which
could ultimately improve the clinical effectiveness and
cost-effectiveness of the service. However, there is a need
to conduct an assessment of satisfaction, usability and
cost of delivery of the new web-enabled telephone health
coaching service (known as IGR3). This trial will there-
fore compare user experience and cost of delivery of
IGR3 with the existing telephone-only health coaching
service (known as IGR2). Further study into the poten-
tial impact of the IGR3 model on the clinical and cost
effective aspects will then be planned.
Methods/Design
Trial design
This trial protocol is written in accordance with standard-
ized reporting guidance from SPIRIT (see Additional
file 1) [23, 24].
This trial is a pragmatic, two-arm, patient-level random-
ized and controlled comparison of two health coaching
services, one of which is already commissioned by Salford
Clinical Commissioning Group and provided in the NHS
by Salford Royal NHS Foundation Trust (i.e. IGR2). As a
comparison of ‘active’ interventions, the expected differ-
ences in effectiveness are likely to be small, and the trial is
not designed primarily to assess differences in clinical
outcomes. Therefore, the objective of this trial is primarily
to assess the acceptability of IGR3 compared with IGR2,
with a secondary aim of examining whether IGR3 will
result in a more efficient delivery method.
This trial will test the hypothesis that a web-enhanced
telephone health coaching intervention for people
with impaired glucose regulation (IGR3) will be more
acceptable than an existing telephone-only health coach-
ing intervention (IGR2). We are also going to examine
whether IGR3 will provide a more efficient delivery
method.
Primary objective
To assess, quantitatively, whether a web-enhanced tele-
phone coaching intervention (IGR3) is more acceptable
than an existing telephone-only coaching intervention
(IGR2) for people with impaired glucose regulation.
Secondary objectives
1. To determine whether the delivery of the IGR3
intervention is more efficient than the existing
commissioned IGR2 while maintaining the
quality of service on a similar level
2. To explore the cost-effectiveness of IGR3 in
comparison with IGR2
3. To explore and compare user and provider
experience of IGR3 and IGR2 interventions
qualitatively
4. To explore the impact, if any, of IGR3 compared
with IGR2 on clinical outcomes relevant to diabetes
prevention in people with impaired glucose
regulation
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Study setting
This trial will be a single-centre study conducted in
Salford, UK. Salford is a city in the north west of England
made up of eight neighbourhoods with a population of
247,000 (34000 aged 65 and over) and ranked as the 16th
most deprived local authority in England out of 326 [25];
approximately 14 % of the adult population are obese [26].
There are 47 general practices in the city, clustered in
eight neighbourhoods.
Interventions
The intervention and control in the trial are both forms of
health coaching. Figures 1 and 2 show the care pathways
for IGR2 and IGR3, respectively. A comparison of the two
services (highlighting their similarities and differences) is
shown in Table 1. The key differences between the arms
are that IGR3 provides patients with a web desktop dash-
board to track progress against patient-centred goals (e.g.
weight, dietary modifications) and a pedometer to monitor
physical activity. Patients in the IGR3 arm also have access
to educational content on the web dashboard in addition
to the paper-based educational materials given to patients
in the IGR2 arm.
Data and outcomes
Demographic and clinical characteristics
Data about demographic and clinical characteristics will
be entered on a case report form by the researcher at
the baseline appointment. We will use sociodemographic
questions from the General Practice Patient Survey [27],
including sex, age, current work situation and qualifica-
tions. Ethnicity will be assessed using the 17 Census
2011 categories [28]. We will include a single-item
health literacy measure, which has demonstrated good
reliability and validity [29, 30], and a measure of the
number and impact of long-term conditions [31].
Primary outcome measure
Patient experience
Patient satisfaction will be assessed using the Client
Satisfaction Questionnaire (CSQ-8), which is a generic
survey instrument used widely in primary care clinical
trials [32]. The CSQ-8 is an eight-item self-administered
questionnaire collected at the end of service delivery and
scored using a four-point Likert scale. The CSQ-8 scores
range from 8 to 32, with higher values indicating higher
satisfaction.
Secondary outcome measures
Costs of intervention
The costs of delivery of IGR2 and IGR3 will be deter-
mined. Hitachi Europe Ltd, with support from Salford
Royal Foundation NHS Trust, will provide a detailed
cost breakdown of the operation of IGR2 and IGR3,
including staff and infrastructure. Data on number and
length of calls for each element of the care pathway in
each arm will be recorded throughout the trial period.
Clinicians responsible for delivery of the intervention
will log call times using a standardized activity log pro-
forma.
Health resources usage
The usage of NHS health care and social services for par-
ticipants will be determined using an adapted health re-
sources questionnaire based on our previous COINCIDE
trial [33]. We will obtain information on rates of utilization
of most of the major elements of health and social care
through linkage with the Salford Integrated Record.
Health outcome measures
1. HbA1c concentration
2. Weight (kg) and body mass index
3. Quality of life: measured using the Euroqol-5D-5 L
(EQ-5D-5 L) [34]. The five-item EQ-5D-5 L is a
generic measure of health-related quality of life,
consisting of the EQ-5D descriptive system and the
EQ Visual Analogue Scale (EQ VAS). The first part
consists of five domains: mobility, self-management,
usual activities, pain, anxiety and depression, with
five levels of severity for each domain. A utility value
can then be calculated based on a population tariff.
The visual analogue scale records an individual’s
self-perceived health, ranging from 0 to 100.
Fig. 1 Care pathway for IGR2. GP, general practitioner; IGR, impaired glucose regulation
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4. Mental Health Inventory-5: this is a five-item scale
that measures general mental health, including
depression, anxiety, behavioural-emotional control
and general positive affect [35].
5. Health experience and self-management: this will be
measured by a modified version of the Summary of
Diabetes Self-Care Activities. It assesses the number
of days per week respondents engage in healthy and
unhealthy behaviours (i.e. eating fruit and vegetable,
eating red meat, undertaking exercise, drinking
alcohol, and smoking) [36].
6. Patient activation: this will be measured by the
Patient Activation Measure. Patient activation is a
measurable outcome associated with higher quality
of life, improved clinical outcomes and increase
engagement with health or social care. The Patient
Activation Measure is a self-report measure of
patient knowledge, skills and confidence in self-
management for long-term conditions [37]. We will
use the short 13-item version [38].
Routine service level data
We will extract data related to a range of processes asso-
ciated with engagement with and completion of the
intervention from the secure web-based intervention
hosted by North West EHealth at the University of
Manchester. These data will allow us to assess patient fi-
delity to the pre-specified service model outlined in
Table 1. Specifically, we will run queries to produce ag-
gregate data for all patients in the IGR3 arm at the end
of the intervention period related to:
1. Completeness of self-assessments
2. Number of times patients logged in to specific pages
3. Number of times patients used ‘contact advisor’
option for additional support
Sample size
The existing IGR2 service is commissioned for 500 pa-
tients per year and we anticipate with the support of
Salford Royal NHS Foundation Trust, general practi-
tioners and diabetes specialist nurses to recruit 200 of
Fig. 2 Care pathway for IGR3. GP, general practitioner; IGR, impaired glucose regulation
Table 1 Comparison of intervention characteristics
Comparison IGR2 IGR3
Materials Patient information
package
Web-based patient tracking
system for diabetes specialist
nurse
Educational materials Web-based patient
information, videos and
data recording
SMS
Patient information package,
including pedometer, self-
assessment link and log-in
details
Educational materials
Providers Diabetes specialist
nurse or dietician
Diabetes specialist nurse or
dietician
Health advisor Health advisor
Administrative support Administrative support
Modes of
delivery
Telephone support Telephone support with
web-based patient tracking
Location of
delivery
Remote Remote
Intervention components
Triage Call from diabetes
specialist nurse
Call from diabetes specialist
nurse
Introduction call Call from health coach Call from health coach
Self-assessment Not applicable Online self-assessment
Action
planning call
Pre-call admin Pre-call admin
Call to patient Call to patient
Post-call admin Post-call admin
Tracking Telephone Online and telephone
Follow-up
calls 1–6
Pre-call admin Pre-call admin
Call to patient Call to patient
Post-call admin Post-call admin
Step-down call
at 9 months
As follow-up call 1 As follow-up call 1
Tailoring Content of intervention
in response to patient
self-evaluation
Content of intervention
in response to patient
self-evaluation
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these patients in 12 months. The trial sample size has
therefore been set at 100 patients per arm, based on a
pragmatic decision concerning the probable recruitment
window. With an estimated 15 % attrition rate, we would
have 90 % power to detect an effect on a standardized
measure of 0.5 on the CSQ-8, and 70 % power to detect
a standardized effect size of 0.4 with a two-sided alpha
of 0.05. A significant difference in CSQ-8 scores in
favour of IGR3 will prove the hypothesis that the web plus
telephone health coaching intervention offers patients a
better care experience than the existing telephone-only
health coaching intervention.
As a comparison of two active treatments, where one
is simply an enhanced version of the other, differences in
clinical outcomes, quality of life and cost-effectiveness
are expected to be relatively small. Therefore, the trial
will not be powered to detect differences for secondary
outcomes.
Eligibility of participants
Participants will be identified from referrals into the
existing Impaired Glucose Regulation Care Call service
provided by Salford Royal NHS Foundation Trust. Referral
criteria into the Impaired Glucose Regulation Care Call
service are:
1. Moderate or high risk score on the Diabetes UK
Risk score tool [39]
and
2. HbA1c = 42–47 mmol/mol (6.0–6.4 %)
or
3. Previous diagnosis of impaired glucose regulation
with 1× confirmatory blood test (HbA1c within the
previous 6 months).
Based on these referral criteria, the eligibility criteria
for the trial recruitment are as follows.
Inclusion criteria
1. Aged 18 years or older
2. HbA1c between 42 and 47 mmol/mol (6.0–6.4 %) in
previous 6 months
3. Access to a telephone and home internet
Exclusion criteria
1. Referred to the face-to-face group impaired glucose
regulation education session and does not go on to
receive telephone-only support
2. Diagnosis of type 2 diabetes: HbA1c of
≥48 mmol/mol (≥6.5 %)
3. Diagnosis of gestational diabetes
4. Does not read or speak English
5. Incapable of participating as indicated by general
practitioner because of dementia, learning
difficulties, vision or motor skills limitations,
serious and enduring mental health problems
Recruitment to the trial
General practice surgeries throughout Salford will be
given promotional literature about Care Call (prepared by
Hitachi Europe Ltd) to raise awareness among general
practitioners about the availability of the service for people
with impaired glucose regulation. All patients referred to
the Care Call service will have a confirmed diagnosis of
impaired glucose regulation and will have had an oppor-
tunity to discuss with their general practitioners the op-
tions available from the Care Call service. Eligible patients
for the service and thus the trial will then be identified
from routine contact with patients’ general practitioners.
In addition, a rapid search and find tool designed by
NorthWest EHealth, FARSITE, will be used to identify
further eligible patients [40]. The FARSITE software
provides a safe, convenient and effective way for general
practitioners to control the recruitment of their patients
into clinical research, while allowing NHS-based re-
searchers to run complex and powerful searches over
anonymized population-level health record data. Because
FARSITE is hosted in a secure environment located at
Salford Royal NHS Foundation Trust, confidentiality of
data is preserved. General practitioner data collected
and processed for FARSITE are transmitted across the
NHS (N3) network, using high grade encryption, by the
secured local NHS data host, the General Practitioner
System Supplier or Apollo Medical Systems Ltd. Patient
demographics data and pseudonymized data are stored
in two separated and encrypted databases. In the
CATFISH study, a research nurse employed by Hitachi
Europe Ltd will run FARSITE searches from general
practices in Salford to generate lists of pseudonymized
patient populations. The clinical teams in practice can
review the selected patients, merge patient contact de-
tails using the letter generation tool and send the letters
to DocMan for print and postal fulfilment services.
These letters will offer patients suspected to have im-
paired glucose regulation to attend for a general practi-
tioner consultation and onward referral to Care Call.
Feasibility searches using FARSITE protocols for im-
paired fasting glucose or impaired glucose tolerance
were run in November 2014 and identified 3852 patients
with suspected impaired glucose regulation. This test
run showed that the FARSITE tool was capable of
identifying patients with impaired glucose regulation and
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that there are sufficient numbers of patients with impaired
glucose regulation who can be referred to the Care Call
service and thus be invited to the CATFISH trial.
After triage, the diabetes specialist nurse at the Care
Call service will pass details of all eligible patients to the
CATFISH trial administrator. The CATFISH trial
administrator will call all patients and confirm personal
details (email and phone number). Each patient is given
a brief overview of the CATFISH trial. The administrator
will confirm that each patient meets the inclusion cri-
teria for the CATFISH trial (access to home internet and
a desktop computer or laptop), and will seek permission
for the University of Manchester research team to contact
them. Those patients who do not wish to be approached
by researchers will be redirected to the existing Care
Call service (IGR2). The contact details of those patients
who do agree to be contacted will be passed to the
University of Manchester research team using a secure
(nhs.net) email service. Within one week, a University of
Manchester researcher will then contact the patient to
discuss involvement in the trial in greater detail, giving
them an opportunity to ask questions about the trial.
Participant timeline
The recruitment window runs from July 2015 to the end
of June 2016. After consenting and undertaking baseline
assessments, participants will enter the IGR3 or IGR2
service, where they will receive active therapeutic con-
tacts for 6 months, followed by a step-down call at
9 months. We will collect measures at baseline, and
9 months (i.e. 3 months after the end of the core contact
period; see Table 1). Recruitment flow and timelines
of assessments are shown in Fig. 3 and Table 2,
respectively.
n=
n=
n=
n=
n=
n=
n=
n=
n=
n=
n=
n=
n=
n=
n=
n=
n=
n= n=
n=
n=
n=
n=
n=
analyzed analyzed
Fig. 3 CONSORT flow diagram. UoM, University of Manchester
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Randomization and allocation concealment
On providing consent, participants will be asked to
complete baseline assessments and are then randomized
using a remote and automated randomization service
provided by the Manchester Academic Health Science
Centre Clinical Trials Unit (MAHSC-CTU) at the
Christie Hospital NHS Foundation Trust, Manchester,
UK. To ensure allocation concealment, randomization
will be by means of a computer-generated code im-
plemented by a MAHSC-CTU employee and shared
by telephone with the Care Call administrator
following correct exchange of a password. The Care
Call administrator will communicate allocations to
Care Call staff (diabetes specialist nurse and health
advisors). Participants will be allocated 1:1 to either
IGR2 or IGR3 using minimization to ensure balance
for age (<40, 40–60, >60 years) and body mass index
(≤18.5, 18.6–24.9, 25.0–29.9). We will use minimization
with a probability weighting of 0.75 to reduce
predictability.
Table 2 SPIRIT Schedule of enrolment, interventions and assessments
STUDY PERIOD
Enrolment Allocation Post-allocation
TIMEPOINT Week 1 Week 2 Week 3 Week 39 (9 months)
Pre-Intervention
Eligibility screen X
Care Call Invitation X
University research team 
invitation X
Informed consent sent X
Allocation X
Interventions:
IGR 2
IGR 3
Assessments:
Sociodemographics X
Height X
Weight
X X
HbA1c
X
CSQ
X
EQ-5D-5L
X X
MHI-5
X X
SDCSCA
X X
PAM
X X
Health care utilization 
X X
CSQ Client Satisfaction Measure, EQ-5D EuroQol five dimensions, HbA1c glycated haemoglobin (A1c), MHI-5 Mental Health Inventory, PAM Patient Activation
Measure, SDSCA Summary of Diabetes Self-Care Activities
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Blinding
It will not be possible to blind participants to treatments
but they will not be formally told which intervention is
an existing service (IGR2) and which intervention is
novel (IGR3). Our researchers at the University of
Manchester will be informed of the MAHSC-CTU
randomization number for each participant by the Care
Call administrator. The MAHSC-CTU randomization
number will become the primary identifier for partici-
pants in the trial. In addition to the Care Call adminis-
trator, the principal investigator (PAC) will be unmasked
to allocations in the event that participants request to be
unblinded. Participants will be unblinded at the end of
the follow-up period, or on withdrawal from the study.
The CATFISH research team at the University of
Manchester will remain blind to treatment allocation
until follow-up assessments have been completed. The
trial statistician will remain blind to treatment allocation.
However, owing to the nature of health economic
analysis, it is not possible to blind the trial health
economist.
Data collection
At the baseline assessment visit, University of Manchester
researchers will record the height and weight of partici-
pants and calculate body mass index using the NHS
Choices body mass index healthy weight calculator [41].
Height will be measured using a Leicester stadiometer on
a firm and even surface. Participants will be asked to
remove their shoes and stand up straight with heels to-
gether, with heels, buttocks and shoulders pressed against
the stadiometer. The University of Manchester researcher
will take the measurement with the participant standing
tall, looking straight ahead with the head upright and not
tilted backwards.
Where participants’ cannot stand, arm span can be
used as an estimate of height, using the formula: total
arm span/1.06 (women) or total arm span/1.03 (men).
Arm span is measured by locating and marking the edge
of the right collar bone (in the sternal notch) with a pen.
Participants will each be asked to place their non-
dominant arm in a horizontal position. The researcher
will check that the patient’s arm is horizontal and in line
with the shoulders. Using a tape measure, the researcher
will measure the distance from the mark on the midline
at the sternal notch to the tip of the middle finger. If the
arm is flat and wrist is straight, the researcher will take a
reading in centimetres and repeat the process for the
dominant arm to calculate the total arm span.
Weight will be measured in kilograms using Seca 875
weighing scales (Class 111 calibrated medical scales) that
conform to ISO 9001:2008. Both height and weight will
be recorded on a case report form. The participant’s
initials is entered onto the front cover of the case report
form, along with general practitioner ‘P’ code and date of
completion. After height and weight have been measured,
participants will be given the baseline questionnaire
to complete. Researchers will be available to answer any
questions the participant may have during completion. Ex-
planation should be given without biasing the participant’s
response. The researcher may also read the questions and
complete the questionnaire if the participant requests
this. After completing the questionnaire, the researcher
will check that all questions have been attempted.
At follow-up, the researcher will contact the partici-
pant by telephone to arrange a convenient time and
place to meet for the follow-up assessment. During this,
call the researcher will remind the participant not to tell
the researcher if they were part of the telephone-only
health coaching group or the web plus telephone health
coaching group. At the follow-up assessment visit, the
researcher will adopt the same procedures undertaken at
the baseline visit to collect and record data on height
and weight. The participants will be given the follow-up
questionnaire to complete and the researcher will adopt
the same procedure undertaken at the baseline visit to
ensure that this questionnaire is completed appropriately.
After completing follow-up assessments, participants
will be invited to attend an appointment at the Clinical
Research Facility at Salford Royal NHS Foundation Trust
for a plasma glucose test to measure HbA1c. All blood
tests will be conducted by nursing staff at the Barnes
Clinical Research Facility, Salford Royal NHS Foundation
Trust. Sample type and volume are fluoride oxalate
(yellow), 1 ml; the reference range is 3.0–6.0 mmol/l.
Laboratory staff will follow the Salford Royal NHS
Foundation Trust protocol for prevention and manage-
ment of potential exposure to blood-borne viruses, includ-
ing needlestick and sharps injuries [42].
Data management
After completion of blood tests and analysis, nursing
staff at the Barnes Clinical Research Facility will be noti-
fied and will collect the results from the laboratory.
Hard copies of the results will then be stored in a
locked, secure area. A member of the CATFISH research
team will visit the Barnes Clinical Research Facility at
least once every two weeks to collect the results. The
results will then be returned to the CATFISH office at
the University of Manchester and stored securely.
Once the research team has collected the HbA1c con-
centration results from the Clinical Research Facility,
they will be screened by the CATFISH Research Nurse.
If the HbA1c concentration falls outside the normal pre-
diabetes range expected (≥48 mmol/mol), the partici-
pant’s general practitioner will be informed by letter of
the result. If the concentration remains within the predi-
abetes range (42–47 mmol/mol) or is within the normal
Coventry et al. Trials  (2016) 17:424 Page 9 of 16
range (<42 mmol/mol) the general practitioner will not
be routinely informed of the result. Blood samples for
HbA1c testing will be automatically archived after ana-
lysis to a secure storage unit in the pathology depart-
ment at Salford Royal NHS Foundation Trust and kept
at 4 °C. They will be kept for a maximum of 2 days and
then sent for incineration.
Demographic and outcome data will be collected in an
anonymized format using paper-based questionnaires
administered face-to-face by the University of Manchester
researchers. Additional data about engagement and deliv-
ery of the intervention will be captured by the secure and
web-based system hosted by NorthWest EHealth at the
University of Manchester. Patient confidentiality will be
protected throughout all phases of data collection and
analysis, in accordance with them UK Data Protection
Act, 1998. The data management policy will adhere to
Research Councils UK Common Principles on Data
Policy and will be created by the principal investiga-
tor in accordance with the University of Manchester’s
intellectual property policy and relevant third-party
agreements. All paperwork will be transferred imme-
diately to the University of Manchester and stored in a
lockable fling cabinet. Paperwork with patient-identifiable
data (consent form, case report form) should be stored
separately from anonymized data (baseline and follow-up
questionnaires).
Names and contact details of patients who decide not
to take part in the trial will be destroyed by the research
team. All other data collected from questionnaires after
consent is given will be anonymized. University of
Manchester policy on storage of personal data is 5 years
after the last publication date of the study or 10 years,
whichever is the greater. Consent forms will be retained
as essential documents, but items such as contact details
will be deleted as soon as they are no longer needed.
Statistical analysis
We will report the trial and analysis according to
CONSORT standards, including full details of use of the
various telephone coaching components [43]. The data
analyst will be masked to treatment allocation.
For most outcomes, we will present descriptive data
on baseline and follow-up scores, to allow assessment of
change in IGR2 and IGR3 patients, as well as compari-
son with outcomes found in pilot evaluations [16, 17].
The focus will be on assessing whether IGR3 achieves at
least as good outcomes as IGR2. This will not involve a
formal assessment of equivalence.
We will formally test for differences between IGR3 and
IGR2 on patient experience using the CSQ-8. Analysis will
follow intention-to-treat principles and a pre-specified
plan. The core analysis will be via linear regression, using
robust standard errors adjusted for the clustering of
patients within practices. We will control for baseline
values of each outcome and design factors. We will apply
multiple imputation to baseline and 9 month variables
with missing values by the chained equations approach
using scores on all primary and secondary outcome
measures (at baseline and follow-up). We will use 20
multiple imputation sets, as this will provide appropriate
stability of results. Analyses will be conducted using
STATA (version 14) with an alpha significance value of
5 %. We will report standardized effect sizes for all
outcomes to aid comparison with published studies.
Health economic analysis
The health economic analysis will comprised two parts,
both of which will assess the cost-effectiveness of health
coaching with a web-based IT platform (IGR3) com-
pared with health coaching alone (IGR2) among people
with prediabetes. The first will be an incremental cost-
effectiveness analysis from a clinical commissioning group
perspective using patient satisfaction and intervention
costs to derive a cost per additional unit of patient satis-
faction. The second analysis will be conducted from an
NHS and personal social services perspective [44]. Costs
will include intervention costs and healthcare and social
services resource costs. The quantity of resource use will
be collected by questionnaire and a set of national average
unit costs will be applied (e.g. [45]). The use of the EQ-
5D-5 L will enable the estimation of quality-adjusted life
years by calculating the area under the curve [46]. An
incremental cost-effectiveness ratio (cost per additional
quality-adjusted life year) will be used to assess cost-
effectiveness of IGR3 in comparison with IGR2. Cost-
effectiveness planes and cost-effectiveness acceptability
curves will be constructed to reflect any uncertainty in
the results and threshold.
Qualitative study
Process evaluations of complex interventions can be
used to explain outcomes through an evaluation of how
casual assumptions about how an intervention might
work are related to the way it was implemented and
how it produces change within particular contexts.
Drawing on guidance from the Medical Research
Council, a focus on understanding implementation (the
what and how of intervention delivery), mechanisms of
impact (pathways to change), and contextual factors can
inform the design and conduct of a process evaluation
[47]. However, the framework proposed by the Medical
Research Council is not easily operationalized in the
absence of a programme theory set out as a logic model.
Programme theory articulates the hypothesized connec-
tions between the programme components and the
outcomes to be assessed and is often underpinned by a
theory of change [48]. Logic models offer a visual way of
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representing the ‘if… then…’ relationships between the
resources needed to deliver the programme, the activities
planned and their outputs, and the intended results of the
programme. Using programme theory to drive the evalu-
ation can help differentiate between programme theory
failure, i.e. whether the intervention failed because of
weaknesses in the underlying theory of change, and
programme implementation failure, i.e. whether the inter-
vention failed because of weaknesses in the way it was
delivered [49].
In this trial, the theory of change presupposes that
health coaching supported by web-enabled self-
monitoring and feedback and education will increase pa-
tient activation, which, in turn, will result in increased
patient satisfaction, reductions in the cost of service de-
livery and positive changes in health behaviours known
to delay or prevent type 2 diabetes (Fig. 4). As such,
greater effects are anticipated among participants in the
web plus telephone coaching group than in the
telephone-only group.
At the heart of this model is the concept of patient
activation, which captures key ingredients known to pre-
dict patients’ capacity to engage in self-managing their
health and use of healthcare: knowledge, skill and confi-
dence [38]. Higher patient activation has been shown to
predict engagement in preventive behaviours, such as
attending regular check-ups, and healthy behaviours,
such as regular exercise, treatment adherence and self-
monitoring [50]. Moreover, activated patients are more
likely to have clinical outcomes, such as HbA1c concen-
tration and body mass index in the normal range [51].
Critically, highly activated patients are more satisfied
with their care experience and have lower rates of hospital
admissions and emergency room use, possibly leading to
reductions in the cost of their care [52, 53].
Taking this theory of change as a starting point, Fig. 5
shows the logic model for the web plus telephone health
coaching intervention tested in this trial. It is read from
left to right, and includes a detailed breakdown of the
resources and activities associated with delivering the
intervention, along with details of the anticipated results,
which include outputs, outcomes and impact over time.
This logic model will facilitate qualitative evaluation of
key programme vantage points related to context, imple-
mentation and outcomes [54]. While this trial is not a
formal test of clinical effectiveness, qualitative evidence
drawn from patient participants and also from health
professionals engaged in delivery of the interventions
will strengthen our understanding about user experience
and impact of what was delivered, leading to greater
opportunities to report about how the interventions
might work in comparable and different contexts.
Specific to the evaluation of IGR3, the evaluation will
also be informed by evidence about dynamic factors that
moderate individual acceptance of IT [55].
Qualitative data collection
Qualitative assessments using semi-structured interviews
with patient participants drawn from both arms of the
trial will take place after quantitative follow-up data have
been collected. Semi-structured interviews offer oppor-
tunities to cover, in-depth, a range of topics relevant to
the research questions, but also allow for exploration
and probing of issues raised during the interview. In this
trial, we will assess patient experience of IGR3 compared
with IGR2, with a focus on understanding whether the
web enhancements led to greater levels of activation and
thus greater engagement with managing their health.
We will also capture data from health professionals
about the experience of implementing web or telephone
health coaching in the context of impaired glucose regu-
lation, with a focus on understanding acceptability and
feasibility of using web platforms to enhance patient
engagement in action planning and behaviour change.
Fig. 4 Theory of change model in CATFISH
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Purposeful maximum variation sampling will be used
to identify patient participants sampled for age, baseline
body mass index and intervention arm. All interviews
will be conducted before outcome analysis is complete,
to allow for a-priori exploration of user acceptance
and experience of implementation. We will aim to
conduct approximately 40 interviews in total, comprising
approximately 20 participants drawn from both arms of
the trial. Where feasible, professionals engaged in the
commissioning, management and delivery of the health
coaching service will also be interviewed. Up to 15 pro-
fessional interviews will be conducted.
Qualitative data analysis
Interviews will be transcribed verbatim and analyzed
thematically using standard approaches informed by
Framework [56]. There are five key stages in this type of
analysis:
1. Familiarization – the transcripts will be read
thoroughly by all researchers to identify key themes.
2. Developing a thematic framework – a framework will
be developed that will be applied to the transcripts.
Following discussions with co-researchers, this frame-
work will then be expanded and refined.
3. Indexing – themes and emerging sub themes will be
labelled and indexed.
4. Charting – framework involves devising a series of
thematic charts or matrices.
5. Mapping and interpretation – the aim is to bring
out the key characteristics and map and interpret
the data as a whole.
A benefit of using Framework analysis is that strategies
and recommendations for practice and policy may be
elicited at an early stage.
Data monitoring
The trial will be supervised independently by members
of the trial steering committee. This committee will
meet twice during the active recruitment period and has
responsibility for monitoring progress of the trial, adher-
ence to the protocol, patient safety and consideration of
new information. Membership includes the principal
investigator (PAC), the chairperson (Professor Christie
Deaton, University of Cambridge, UK), and two other in-
dependent members (Dr Barbara Barett, King’s College
London, UK and Dr Daniel Hind, University of Sheffield,
UK). The trial statistician will attend when appropriate.
At the chair’s discretion, an observer from Hitachi
Self -
Fig. 5 Logic model of programme components in CATFISH. DNS, domain name system
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Europe Ltd will attend the trial steering committee.
Given the nature of this trial it is unlikely that there are
critical patient safety issues for a separate data monitor-
ing and ethics committee to consider and there will be
no formal stopping rules. Terms of reference of the trial
steering committee are available on request from the
principal investigator.
Adverse event reporting
An adverse event is any untoward and unexpected med-
ical occurrence in a patient or clinical study subject. Ad-
verse events are likely to be rare but should be reported
to the principal investigator by the researcher or Care
Call team. Although CATFISH is a trial of a non-
investigational medicinal product, serious adverse events
that are both related to the research procedures and are
unexpected should be reported immediately (within
24 hours) either orally or in writing to the research
sponsor (University of Manchester). This immediate re-
port will be followed by a detailed written report sent to
the NHS Research Ethics Committee that granted ap-
proval for the trial (East of England – Cambridgeshire
and Hertfordshire) within 15 days of the study investiga-
tor becoming aware of the event.
Research ethics
The trial will be conducted in accordance with the UK
Department of Health’s Research Governance Framework
in health and social care and adhere to the ethical
principles of the Helsinki Declaration [57]. All re-
search staff involved in the conduct of the trial will
meet the standards laid out in the ICH Harmonised
Tripartite Guideline for Good Clinical Practice [58].
All participants will be offered a high street voucher
worth £20 after completing baseline and the follow-
up assessments.
Amendments
Substantial amendments will be communicated to the
NHS Research Ethics Committee for the East of England
(Cambridgeshire and Hertfordshire), following the
process outlined by the NHS Health Research Authority.
Since starting the trial one substantial amendment has
been submitted and granted. This related to permission
for a promotional flyer to be used in general practice to
promote the Impaired Glucose Regulation Care Call
service among general practitioners. This amendment
also included provision for the eligibility criteria to be
changed to bring the trial into line with evaluation
parameters proposed by the NHS National Diabetes
Prevention Programme, i.e. only patients with a HbA1c
concentration between 42 and 47 mmol/mol in the
previous 6 months can be referred into the Care Call
service and subsequently invited to take part in the trial.
Access to data and dissemination policy
As the sponsor of the trial, the University of Manchester
will remain the custodians of the data collected from
participants during the trial and will not share data with
any third party, including private companies, without
the consent of the participants. Data will not be released
to third parties or private companies (including the
funder) before the trial has been completed and will be
analyzed by an independent evaluation team at the
University of Manchester. No interim analysis is planned
and no interim data will be shared with the funder or
third parties. In recognition of the importance of
transparency and need to increase trust in clinical trial
results both Hitachi Europe Ltd, and the University of
Manchester will agree to data sharing in accordance
with proposals outlined by the International Committee
of Medical Journal Editors, which state that authors
share with others the deidentified individual-patient data
underlying the results presented in the trial report
(including tables, figures, and appendices or supplemen-
tary material) no later than 6 months after publication
[59]. Hitachi, as the funder of the trial and as owners of
the technology to be tested, may wish to invoke a brief
embargo (up to 3 months) on data sharing before publi-
cation in an open-access journal.
Discussion
Interventions that rely solely on telephone contact (with
no self-monitoring of blood glucose) are no more effective
than standard care in improving glycaemic control [60],
signalling an opportunity to further develop and evaluate
interventions that combine telephone interventions with
self-monitoring and electronic transfer of data between
patients and healthcare providers. Before embarking on
expensive and time-consuming trial assessment of clinical
effectiveness and cost-effectiveness, however, a key chal-
lenge is to understand from the patient perspective if
enhancing telephone health coaching interventions with
IT platforms improves acceptability and usability and
thereby engagement in diabetes prevention programmes.
This trial will offer important insights about whether a
web-based IT platform can enhance engagement in a tele-
phone health coaching intervention provided by health
advisors for people with impaired glucose regulation. The
results will have implications for the design of future
definitive cost-effectiveness trials in settings where there is
no existing diabetes prevention programme.
The trial design is potentially limited by restrictions on
participant recruitment. Currently, referral into the Care
Call service at Salford Royal NHS Foundation Trust is
heavily reliant on general practice and there are limited
routes into the service from other sources in the com-
munity, e.g. pharmacy and public health. Participants in
the CATFISH trial will therefore primarily be drawn
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from patients already ‘in the system’ and known to gen-
eral practitioners and may have been given behaviour
change advice in the past. Additionally, achieving our
recruitment target may be jeopardized by only sourcing
participants for the CATFISH trial from referrals into
the Care Call service – recruitment into the trial will be
contingent on sufficient throughput in the clinical
service. However, Salford Royal NHS Foundation Trust
is one of seven demonstrator sites for the NHS National
Diabetes Prevention Programme in the NHS and there
is an ongoing commitment to increase capacity in the
Care Call service, with a likely benefit for the CATFISH
trial. Furthermore, the Care Call service attracts referrals
from all eight neighbourhoods across Salford, increas-
ing opportunities to recruit participants with different
socio-economic profiles. The design and recruitment
strategy are thus pragmatic and thus more likely to
be generalizable.
Working with industry partners in health services
research is novel and presents unique challenges, not
least the need to maintain independence. Hitachi Europe
Ltd, have invested in the Care Call service at Salford
Royal NHS Foundation Trust to improve efficiencies,
such as employing an administrator and a research nurse
to expedite quality referrals into the service. With the
support of the trial steering committee, the CATFISH
trial is being run as an independent evaluation and we
have ensured that sufficient safeguards are in place to
preserve independence throughout all phases of the trial.
This includes a commitment to open-access publication
and data sharing, in keeping with policies to prevent
publication and outcome reporting bias of clinical trials.
Trial status
Trial registration was initiated prospectively with ISRCTN
on 23 April 2015. Failure of administrative functions on
the part of BioMed Central who host and curate ISRCTN
and the University of Manchester led to delay in payment
and registration was not finalised until 1 July 2015. The
recruitment started on 30 June 2015, after the initiation
of public registration.
Recruitment to the trial began in June 2015 and com-
pleted in May 2016. A total of 209 participants were
recruited and randomized. The trial is now in follow-up
and data collection will be completed at the latest in
March 2017; results will be available in May 2017.
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